Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Keytruda (pembrolizumab)
pCPA File Number:
21139
Negotiation Status:
Negotiations were not pursued
Indication(s):
Metastatic Urothelial Carcinoma (first line)
Sponsor/Manufacturer:
Merck Canada Inc.
CADTH Project Number:
pCODR 10177
pCPA Engagement Letter Issued:
2019-11-29
Negotiation Process Concluded:
2019-11-29